Cardiovascular disease remains the leading cause of death globally, presenting a significant challenge to medical researchers seeking more effective treatments. Now, a new “heart-on-a-chip” (HOC) platform developed by scientists in Canada offers a promising avenue for testing drug responses and understanding disease mechanisms in a way that more closely mimics the human heart. This innovative technology could accelerate the development of personalized therapies and improve outcomes for millions.
The key advancement lies in the HOC’s ability to provide real-time tracking of cardiac activity at both macro and micro scales, a capability lacking in previous models. This detailed monitoring allows researchers to observe how engineered heart tissue responds to various stimuli, offering unprecedented insights into the complexities of cardiovascular function. The development represents a “significant advance in cardiac tissue engineering and pharmacological testing,” according to the research team.
Researchers from multiple Canadian institutions detailed their work in a recent paper, outlining how they created the HOC using cardiac muscle and connective tissue cells harvested from rats. These cells were embedded in a gel-like matrix and seeded onto flexible silicon-based chips. Two types of sensors were integrated into the HOCs: elastic pillars to measure macro-scale forces generated by the beating tissue, and flexible hydrogel-based microsensors to capture local mechanical stresses at the cellular level – averaging just 50 micrometers in size.
This level of detail is crucial because many cardiovascular diseases (CVDs) are linked to dysfunction within individual heart muscle cells, known as cardiomyocytes. By measuring cellular function, scientists aim to prevent heart failure in patients with CVDs. The ability to observe cell-generated forces is too critical, as these forces influence cardiac tissue formation, remodeling, and overall efficiency, as well as processes like wound healing and cancer progression.
Drug Screening and Future Applications
To demonstrate the HOC’s capabilities, the researchers tested the effects of two well-studied compounds: norepinephrine (also known as noradrenaline) and blebbistatin. Norepinephrine, used to increase heart activity and blood pressure, produced the expected response, while blebbistatin, an inhibitor of muscle activity, decreased contractile activity as predicted. This confirmed the HOC’s ability to accurately forecast how cardiac force generation and heart rhythms respond to common medications. “The ability to observe the tissue’s response to different compounds in real time represents a major advantage for preclinical development and translational research,” said first author Ali Mousavi, a biomedical engineer at the University of Montreal.
Looking ahead, the research team plans to build heart tissues using cells from patients with specific cardiac conditions, including dilated cardiomyopathy – a genetic heart muscle disease that can lead to heart failure – and arrhythmias, a range of disorders causing irregular heartbeats. This approach could pave the way for personalized medicine, where treatments are tailored to an individual’s unique cellular profile.
Towards Precision Health
the goal is to enable doctors to test potential treatments on a patient’s own cells before prescribing medication. As senior author Houman Savoji, a mechanical and biomedical engineer at the University of Montreal, stated, “This breakthrough brings us even closer to true precision health, by giving us the ability to identify the most effective medication for each person before treatment is even administered.” The development of heart-on-a-chip technology represents a significant step forward in cardiovascular research and offers hope for more effective treatments for the world’s leading cause of death.
Further research will focus on refining the HOC platform and expanding its applications to model a wider range of cardiovascular diseases. The potential for this technology to accelerate drug discovery and improve patient outcomes is substantial, and ongoing studies will be crucial in realizing its full potential.
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential of heart-on-a-chip technology? Share your comments below!
